H. Lundbeck AS's EBIT per Share for the
three
months ended in Mar. 2026 was €0.29.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.74.
During the past 12 months, the average EBIT per Share Growth Rate of H. Lundbeck AS was 56.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 22.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -4.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for H. Lundbeck AS's EBIT per Share or its related term are showing as below:
FRA:LDBA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -69.2 Med: 12.5 Max: 255
Current: 22.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of H. Lundbeck AS was 255.00% per year. The lowest was -69.20% per year. And the median was 12.50% per year.
FRA:LDBA's 3-Year EBIT Growth Rate is ranked better than 72.01% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs FRA:LDBA: 22.80
H. Lundbeck AS's EBIT for the
three
months ended in Mar. 2026 was €288 Mil.
H. Lundbeck AS (FRA:LDBA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
H. Lundbeck AS EBIT per Share Related Terms
H. Lundbeck AS EBIT per Share Historical Data
* Premium members only.
The historical data trend for H. Lundbeck AS's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H. Lundbeck AS (FRA:LDBA) has a EBIT per Share of €0.74 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on H. Lundbeck AS and its competitors. According to the industry distribution chart, H. Lundbeck AS ranks #227 out of 811 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is H. Lundbeck AS's EBIT per Share too high?
H. Lundbeck AS's current EBIT per Share is €0.74. Based on the distribution chart, H. Lundbeck AS ranks #227 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #227 out of 811 companies for EBIT per Share. This puts H. Lundbeck AS in the upper half of its industry. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current EBIT per Share is €0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.31, compared to a current price of €5.93 — trading 6.1% below its estimated fair value. The current EBIT per Share is €0.74. H. Lundbeck AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current EBIT per Share is €0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of €5.93 is trading 6.1% below its estimated GF Value™ of €6.31.
GuruFocus considers H. Lundbeck AS to be Fairly Valued.
Key valuation signals for FRA:LDBA:
EBIT per Share: €0.74
GF Value™: €6.31 vs. price of €5.93 (6.1% below fair value)
No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
81GF Score
Get the complete analysis for FRA:LDBA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LDBA has been successfully added to your 
